Loading...
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
Ofatumumab Arzerra(®) is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has bee...
Na minha lista:
| Udgivet i: | Ther Clin Risk Manag |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5530057/ https://ncbi.nlm.nih.gov/pubmed/28790834 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S140023 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|